A new multicenter study shows use of Medtronic’s InterStim Therapy via sacral nerve stimulation reduced incontinent episodes and improved quality of life in most patients with chronic fecal ...

Certain healthcare conditions often go unspoken, leading to silent struggles that affect the lives of many. Overactive bladder (OAB) and fecal incontinence (FI) are two such conditions, impacting ...

ZANESVILLE – Dr. Mitesh Parekh, a urogynecologist with Genesis Urogynecology, has been recognized by Medtronic, a medical device company, for outstanding contribution in positively impacting the lives ...

The FDA has approved Medtronic plc’s next-generation sacral neuromodulation (SNM) system, Interstim X, giving patients a recharge-free option with a 10-year+ lifespan. This newest member of the ...

NASHVILLE, Tenn. (Ivanhoe Newswire) – It’s a taboo topic that nobody talks about but, almost one in six Americans suffer with urinary or bowel incontinence. That’s more than the number of people with ...

WASHINGTON, D.C.—Sacral neuromodulation with InterStim Therapy is safe and well tolerated as a treatment for patients with overactive bladder and those with urinary retention, French investigators ...

BARCELONA—Sacral neuromodulation (SNM) with Interstim Therapy is significantly better than an additional trial of standard medical treatment (SMT) for patients with refractory overactive bladder (OAB) ...

Medtronic is upping the ante in a patent dispute with competitor Axonics Inc. that has already lasted more than four years. The dispute centers on Medtronic’s InterStim device, an implanted ...

announced today that newly published data from a multicenter, prospective trial show that sacral nerve stimulation using Medtronic InterStim® Therapy reduced incontinent episodes and increased quality ...

DUBLIN, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that its recently FDA-approved InterStim™ Micro neurostimulator for sacral ...